In their research, Bonnefoi et al. [70] performed a phase II trial in women with ER-negative and AR-positive (molecular apocrine-like HER2-negative) metastatic or inoperable locally advanced BC with the aim of assessing the efficacy and safety of AA plus prednisone. Here, AR is linked to breast cancer.